Yoshihiro Otaki
President chez BioFrontier Partners, Inc.
Profil
Yoshihiro Otaki is the founder of Human Metabolome Technologies, Inc. which was founded in 2003.
He held the title of Chairman from 2003 to 2011.
He is currently the Chairman and Representative Director at Healthcare Innovation Co. Ltd.
He is also an Outside Director at GeneCare Research Institute Co., Ltd.
since 2000, a Director at Cell-Medicine, Inc., and the President of BioFrontier Partners, Inc. since 1999.
Dr. Otaki received his doctorate degree from Tohoku University in 1979 and his undergraduate degree from the same university in 1973.
Postes actifs de Yoshihiro Otaki
| Sociétés | Poste | Début |
|---|---|---|
BioFrontier Partners, Inc.
 BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | President | 10/03/1999 |
GeneCare Research Institute Co., Ltd.
 GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Directeur/Membre du Conseil | 20/12/2000 |
Healthcare Innovation Co. Ltd.
 Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Président | - |
Cell-Medicine, Inc.
 Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Directeur/Membre du Conseil | - |
Anciens postes connus de Yoshihiro Otaki
| Sociétés | Poste | Fin |
|---|---|---|
| HUMAN METABOLOME TECHNOLOGIES, INC. | Fondateur | - |
Formation de Yoshihiro Otaki
| Tohoku University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HUMAN METABOLOME TECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
BioFrontier Partners, Inc.
BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | Finance |
GeneCare Research Institute Co., Ltd.
GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Health Services |
Healthcare Innovation Co. Ltd.
Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Finance |
Cell-Medicine, Inc.
Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Health Technology |
